Clinical Trial Detail

NCT ID NCT04209725
Title A Study of CPX-351 (Vyxeos) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors SCRI Development Innovations, LLC
Indications

acute myeloid leukemia

Therapies

CPX-351 + Quizartinib

Age Groups: adult senior

Additional content available in CKB BOOST